CA2588465C - Pharmaceutical composition containing an anti-nucleating agent - Google Patents

Pharmaceutical composition containing an anti-nucleating agent Download PDF

Info

Publication number
CA2588465C
CA2588465C CA2588465A CA2588465A CA2588465C CA 2588465 C CA2588465 C CA 2588465C CA 2588465 A CA2588465 A CA 2588465A CA 2588465 A CA2588465 A CA 2588465A CA 2588465 C CA2588465 C CA 2588465C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutical composition
salt
employed
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2588465A
Other languages
English (en)
French (fr)
Other versions
CA2588465A1 (en
Inventor
Maria T. Cruanes
Wei Xu
Laura M. Artino
Honggang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36565788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2588465(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2588465A1 publication Critical patent/CA2588465A1/en
Application granted granted Critical
Publication of CA2588465C publication Critical patent/CA2588465C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2588465A 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent Expired - Fee Related CA2588465C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63285904P 2004-12-03 2004-12-03
US60/632,859 2004-12-03
PCT/US2005/043675 WO2006060681A2 (en) 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent

Publications (2)

Publication Number Publication Date
CA2588465A1 CA2588465A1 (en) 2006-06-08
CA2588465C true CA2588465C (en) 2013-10-01

Family

ID=36565788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2588465A Expired - Fee Related CA2588465C (en) 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent

Country Status (9)

Country Link
US (1) US8771733B2 (enExample)
EP (2) EP3165220B2 (enExample)
JP (3) JP2008521929A (enExample)
CN (1) CN101068533B (enExample)
AU (1) AU2005311714B2 (enExample)
CA (1) CA2588465C (enExample)
ES (1) ES2727577T5 (enExample)
TR (1) TR201907729T4 (enExample)
WO (1) WO2006060681A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
BRPI0518741A2 (pt) * 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
EP3165220B2 (en) 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent
CA2667167C (en) * 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CN101197832B (zh) * 2007-12-13 2012-01-25 华为技术有限公司 一种实现iptv业务的方法、系统、装置
US8742105B2 (en) 2009-06-02 2014-06-03 Hetero Research Foundation Polymorphs of raltegravir potassium
AU2010313571B2 (en) * 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
ES2524380T3 (es) * 2010-04-01 2014-12-05 Teva Pharmaceutical Industries Ltd. Sales de raltegravir y formas cristalinas de las mismas
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
US12472475B2 (en) 2018-02-02 2025-11-18 The General Hospital Corporation Methods of supercooling aqueous samples
WO2021148992A1 (en) 2020-01-23 2021-07-29 Lupin Limited Pharmaceutical compositions of raltegravir
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
AU6329599A (en) † 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
BR9916583A (pt) * 1998-12-25 2001-09-25 Shionogi & Co Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
CA2406562C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US7115565B2 (en) † 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DE122009000048I1 (de) 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
EP1499391A2 (en) 2002-04-10 2005-01-26 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
WO2004058756A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
PT1583542E (pt) † 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
EP3165220B2 (en) † 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
UA87884C2 (uk) † 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
US9968607B2 (en) † 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof

Also Published As

Publication number Publication date
WO2006060681A2 (en) 2006-06-08
JP2013063999A (ja) 2013-04-11
WO2006060681A3 (en) 2006-10-12
AU2005311714B2 (en) 2010-09-30
ES2727577T5 (en) 2025-04-02
EP1819323A2 (en) 2007-08-22
CN101068533B (zh) 2011-04-27
ES2727577T3 (es) 2019-10-17
EP1819323A4 (en) 2012-07-18
JP2012184250A (ja) 2012-09-27
US8771733B2 (en) 2014-07-08
CN101068533A (zh) 2007-11-07
JP2008521929A (ja) 2008-06-26
US20080118559A1 (en) 2008-05-22
EP3165220A1 (en) 2017-05-10
EP1819323B2 (en) 2023-03-22
AU2005311714A1 (en) 2006-06-08
EP3165220B2 (en) 2024-11-13
TR201907729T4 (tr) 2019-06-21
CA2588465A1 (en) 2006-06-08
EP3165220B1 (en) 2019-04-03
EP1819323B1 (en) 2016-11-16

Similar Documents

Publication Publication Date Title
JP2012184250A (ja) 抗核形成剤を含有する医薬組成物
IL183615A (en) Pharmaceutical formulation of HIV carboxamide amide-containing inhibitors containing the controlled-release composition
WO2003082805A1 (en) Low water-soluble venlafaxine salts
WO2007087188A2 (en) Taste-masked tablets and granules
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
JP6123795B2 (ja) 放出制御医薬組成物
HK1133193A1 (en) Pharmaceutical compositions comprising nilotinib or its salt

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141202